Definitive Healthcare Corp 8-K, filed Jul 8, 2024
Definitive Healthcare Corp. (DH)
About this 8-K
Definitive Healthcare Corp filed this 8-K on July 8, 2024, reporting on events of July 4, 2024.
Items reported
- Item 5.02: Director or officer change, or executive pay
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
Commission File Number |
||
|
|
|
|
||
(State |
|
(IRS Employer |
|
|
|
|
|
|
|
(Address of Principal Executive Offices) |
|
Registrant’s telephone number, including area code |
Not Applicable |
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading |
|
Name of Each Exchange on Which Registered |
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As previously disclosed, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) appointed Kevin Coop to the position of Chief Executive Officer (“CEO”) and as a member of the Board, each effective June 24, 2024 (the “Start Date”). In connection with Mr. Coop’s appointment as CEO, the Company entered into an Employment Agreement with Mr. Coop, dated as of May 20, 2024 (the “Employment Agreement”), the terms of which were disclosed in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on May 24, 2024. In addition to the terms set forth in the Employment Agreement, on July 4, 2024, the Company granted to Mr. Coop an award of 186,192 time-vesting restricted stock units (the “RSU Award”) with respect to the Company’s Class A Common Stock, par value $0.001 per share, vesting 25% on July 1, 2025 and 6.25% per quarter thereafter until fully vested over the subsequent three years, subject to Mr. Coop’s continued employment through each applicable vesting date. The RSU Award is intended to make up for a shortfall in the equity grant value delivered to Mr. Coop due, in part, to share price volatility between the dates surrounding the announcement of Mr. Coop’s appointment and his Start Date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
DEFINITIVE HEALTHCARE CORP. |
||
|
|
|
By: |
/s/ Richard Booth |
|
Name: |
Richard Booth |
|
Title: |
Chief Financial Officer |
|
|
|
|
Date: July 8, 2024 |
||